1. Home
  2. FNKO vs MGNX Comparison

FNKO vs MGNX Comparison

Compare FNKO & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Funko Inc.

FNKO

Funko Inc.

HOLD

Current Price

$6.12

Market Cap

323.3M

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

BUY

Current Price

$3.67

Market Cap

262.4M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
FNKO
MGNX
Founded
2017
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
323.3M
262.4M
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
FNKO
MGNX
Price
$6.12
$3.67
Analyst Decision
Buy
Buy
Analyst Count
2
7
Target Price
$7.25
★ $8.00
AVG Volume (30 Days)
★ 860.7K
463.0K
Earning Date
11-05-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $908,209,000.00
$149,500,000.00
Revenue This Year
$2.98
N/A
Revenue Next Year
$8.18
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$2.72
$1.30
52 Week High
$7.35
$5.08

Technical Indicators

Market Signals
Indicator
FNKO
MGNX
Relative Strength Index (RSI) 60.61 41.25
Support Level $5.13 $3.36
Resistance Level $6.58 $4.36
Average True Range (ATR) 0.26 0.22
MACD 0.09 -0.04
Stochastic Oscillator 83.02 21.28

Price Performance

Historical Comparison
FNKO
MGNX

About FNKO Funko Inc.

Funko Inc is an USA based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: